{"filings":[{"id":814961,"accession_number":"0001193125-26-254476","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-06-03T10:01:45+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA announces clinical collaboration with Roche for PRMT5 + pan-RAS combo in MTAP-deleted PDAC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDE892 (PRMT5 inhibitor) to be combined with Roche's RG6505 (pan-RAS inhibitor) in MTAP-deleted, RAS-mutant pancreatic cancer.","IDEAYA will sponsor the Phase 1 combination trial; Roche will supply RG6505.","MTAP deletion occurs in up to 40% of PDAC; almost all such cases have co-occurring RAS mutations.","Both companies retain full commercial rights to their compounds; joint governance oversees the study.","Triplet combination with IDE397 (MAT2A inhibitor) may be evaluated with joint approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777881,"accession_number":"0001193125-26-251399","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-06-01T20:05:32+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Darovasertib + crizotinib achieved median PFS 6.9 months vs 3.1 months for investigator's choice (HR=0.42, p<0.0001) by BICR, reducing risk of progression by 58%.","Objective response rate 37.1% (combo) vs 5.8% (control) by BICR; disease control rate 73.3% vs 31.1%.","Grade 3/4 TRAEs 40.6% vs 37.0%; treatment-related discontinuations low (darovasertib 2.5%, crizotinib 10.0% vs ICT 19.0%).","FDA agreed to review darovasertib NDA under Real-Time Oncology Review; submission expected in H2 2026.","Overall survival data immature but early trend favoring combo; future analysis will support full approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94619,"accession_number":"0001193125-26-206806","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IDEAYA files new S-3ASR; $156.6M ATM capacity remains under Jefferies agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new automatic shelf registration (S-3ASR) to replace expiring June 2026 shelf; effective May 5, 2026.","Prior sales under ATM totaled $193.4M gross proceeds; remaining capacity of $156.6M under same Sales Agreement.","ATM prospectus supplement filed for at-the-market stock sales via Jefferies; no change in terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94618,"accession_number":"0001193125-26-204944","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.","NDA submission for darovasertib under FDA RTOR planned H2 2026; complete data at ASCO 2026.","Cash equivalents and marketable securities $972.9M as of March 31, 2026; runway unchanged into 2030.","Net loss for Q1 2026 was $98.5M vs $83.3M in Q4 2025; R&D expenses $95.7M.","Appointed Dr. Theodora Ross as Chief Development Officer in February 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":6560000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94617,"accession_number":"0001193125-26-151893","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA announces Phase 2/3 trial met primary endpoint; darovasertib combo reduces progression risk by 58%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Darovasertib + crizotinib reduced risk of disease progression by 58% (HR 0.42, p<0.0001) in 1L HLA-A*02:01-negative mUM.","Median PFS 6.9 months vs 3.1 months for investigator choice therapy (ICT) arm.","ORR 37.1% vs 5.8% for ICT; 5 complete responses in combo arm, none in ICT.","NDA submission to FDA targeted for second half of 2026.","Safety profile manageable; Grade 3+ events included diarrhea, syncope, hypotension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94616,"accession_number":"0001193125-26-148777","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.","IDEAYA sponsors the combination study; AstraZeneca supplies Imfinzi.","IDE849 Phase 1 global trial ongoing in DLL3-upregulated solid tumors including SCLC, NECs, NETs, melanoma.","No financial terms of the collaboration disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107129,"accession_number":"0001193125-26-052741","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA expects topline PFS data from darovasertib Phase 2/3 trial by late March 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["130 required PFS events confirmed by BICR; topline results from OptimUM-02 trial (1L HLA*A2-negative mUM) expected ~last week of March 2026.","Cash, cash equivalents and marketable securities ~$1.05B as of Dec 31, 2025; expected to fund operations into 2030.","Q4 2025 net loss $83.3M vs $130.3M in Q4 2024; R&D expenses $86.6M, down from $140.2M (prior Q4 included $75M license payment to Hengrui).","GSK terminated Collaboration Agreement; Werner Helicase (IDE275) and Pol Theta (IDE705) programs to be transferred to IDEAYA.","Anticipates initiation of IDE849 monotherapy registrational study in 2L+ SCLC/NEC by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":218710000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107128,"accession_number":"0001193125-26-009653","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA lays out 2026 goals: darovasertib PFS data Q1, three Phase 3 trials, IDE849 registrational start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.","Darovasertib to be in three randomized Phase 3 trials (OptimUM-02, -10, -11) across UM stages by H1 2026.","IDE849 (DLL3 TOP1 ADC) registrational monotherapy study in SCLC/NEC targeted to start by end of 2026.","IDE034 (B7H3/PTK7 ADC) Phase 1 dose escalation to begin Q1 2026; IDE892 (PRMT5) Phase 1 in Q1 2026.","Cash of $1.1 billion as of Sep 30, 2025, expected to fund operations into 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107127,"accession_number":"0001193125-26-009641","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"IDEAYA posts corporate presentation at JPM 2026; no new material data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation posted to investor website dated January 12, 2026, for JPM Healthcare Conference.","No financial results, clinical data updates, or material events explicitly reported in the 8-K filing text.","Presentation contains forward-looking statements and safe harbor language; no specific milestones or numbers cited.","Filing is under Item 7.01 Regulation FD Disclosure; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123467,"accession_number":"0001193125-25-317541","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.","Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.","IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.","Cash runway guidance into 2030 remains unchanged despite the termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123466,"accession_number":"0001193125-25-309716","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GSK terminates collaboration; IDEAYA regains IDE275 and IDE705; cash runway unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GSK terminates Collaboration, Option and License Agreement effective 90 days after Dec 4, 2025; programs transferred back to IDEAYA.","IDEAYA to evaluate strategic options for IDE275 (Werner Helicase) and IDE705 (Pol Theta) in 2026.","Company reaffirms cash runway into 2030, unchanged by the termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123465,"accession_number":"0001193125-25-263383","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA reports Q3 net income $119.2M, cash $1.14B; darovasertib partnership with Servier closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $119.2M vs Q2 net loss of $77.5M; collaboration revenue $207.8M from Servier license.","Cash, equivalents, marketable securities $1.14B (up from $991.9M Q2); funded into 2030.","Darovasertib Phase 2/3 OptimUM-02 median PFS data due by year-end 2025 to Q1 2026; trial nearing full enrollment.","IDE849 DLL3 ADC in SCLC: 80.0% ORR in 2L patients at 2.4 mg/kg; median PFS 6.7 months across all lines.","IND clearance for IDE892 (PRMT5) in Q3; IND filed for IDE034 (bispecific ADC); IDE574 IND on track for year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":207834000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123464,"accession_number":"0001193125-25-243558","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA reports Phase 2 darovasertib data: median OS 21.1 mo in 1L mUM; 57% eye preservation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Darovasertib + crizotinib in 1L mUM: median OS 21.1 mo (historical ~12 mo), median PFS 7.0 mo, ORR 34%, DCR 90%.","Neoadjuvant darovasertib in primary UM: 83% (78/94) of patients achieved tumor shrinkage; 54% >=20% shrinkage.","Among patients recommended for enucleation, 57.1% (24/42) achieved eye preservation; in those with >=20% shrinkage, rate jumped to 95%.","Predicted radiation reduction: 70% of Cohort 2 patients saw any reduction in predicted dose to critical eye structures; 64.9% had reduced 3-year vision loss risk.","FDA Breakthrough Therapy Designation for neoadjuvant darovasertib; registration-enabling Phase 2/3 OptimUM-02 targeting median PFS data by year-end 2025 to Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140139,"accession_number":"0001193125-25-197605","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA reports positive Phase 1 data for IDE849 in SCLC, positive Phase 2 darovasertib in UM, positive IDE397 combo data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDE849 (DLL3 ADC) showed 73.2% ORR (52/71) and 47.9% confirmed ORR in SCLC at >=2.4 mg/kg; median PFS 6.7 months.","Darovasertib neoadjuvant UM trial: 76% (16/21) achieved >=20% tumor shrinkage; 48% had >=20% reduction in simulated radiation dose.","IDE397 (MAT2A) + Trodelvy in MTAP-del UC: 33% ORR at DL1 (3cPR), 57% ORR at DL2 (3cPR+1uPR); DCR up to 100%.","Phase 3 OptimUM-10 trial for darovasertib in neoadjuvant primary UM initiated Q2 2025; additional data at ESMO Oct 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140138,"accession_number":"0001193125-25-193238","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.","Upfront $210M; up to $100M development/regulatory milestones and $220M commercial milestones.","Royalties on ex-US net sales: mid-teens to low-twenties percent.","Cash runway extended by at least 12 months; expects funding into 2030 under current plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140137,"accession_number":"0000950170-25-102353","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.","Cash, cash equivalents and marketable securities ~$992M as of June 30, 2025, down from $1.05B at March 31, 2025.","Darovasertib/crizotinib Phase 2/3 trial in 1L HLA-A2-negative MUM enrolled over 350 patients; median PFS data on track for YE2025 to potentially enable accelerated approval filing.","Three IND submissions by YE2025: IDE892 (PRMT5), IDE034 (B7H3/PTK7 bispecific ADC), IDE574 (KAT6/7).","IDEAYA to host R&D Day on Sept 8, 2025, with multiple clinical data updates including neoadjuvant darovasertib and IDE397 combo data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157785,"accession_number":"0001193125-25-151257","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEAYA Biosciences appoints Joshua Bleharski as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Bleharski, Ph.D. appointed CFO and Principal Financial Officer effective June 26, 2025.","Appointment made by Board of Directors; no departure of prior CFO or compensation disclosed.","Bleharski assumes responsibilities as CFO; no other leadership changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157784,"accession_number":"0001193125-25-145830","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IDEAYA shareholders elect Stein and Morrison; Morrison with 45% withheld votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jeffrey L. Stein elected with 69.1M votes for (89.7%); Scott W. Morrison elected with 42.1M for (54.7%), 34.9M withheld.","Ratification of PwC as auditor for FY2025: 79.6M for, 228.6K against, 190.4K abstain.","Advisory say-on-pay passed with 59.8M for (77.8%), 17.0M against, 194.7K abstain.","Broker non-votes of 3.03M shares on director election and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157783,"accession_number":"0000950170-25-063938","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA Q1 2025 net loss $72.2M; cash ~$1.05B funds ops into 2029; darovasertib enrollment >300 pts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and securities $1.05B as of March 31, 2025, supporting updated runway into 2029.","Net loss of $72.2M in Q1 2025; R&D expenses $70.9M (down from $140.2M Q4 2024 incl. one-time $75M license payment).","Over 300 patients enrolled in darovasertib + crizotinib 1L MUM registrational trial; median PFS readout targeted by YE 2025.","FDA Breakthrough Therapy designation for neoadjuvant darovasertib in primary UM; Phase 3 design finalized after Type D meeting.","Three IND filings targeted in 2025: PRMT5 (IDE892), B7H3/PTK7 ADC (IDE034), KAT6/7 (IDE574); IDE849 Phase 1 started in US."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157782,"accession_number":"0001193125-25-071309","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Susan Kelley to step down from IDEAYA board, move to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan L. Kelley, M.D. will not stand for re-election at the 2025 annual meeting of stockholders.","She will resign from the Board immediately after the Annual Meeting.","Kelley intends to transition to Chair of the new Clinical Advisory Board expected before the meeting.","Board size will decrease to seven directors effective after the Annual Meeting.","Departure is not due to any disagreement with the Company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176153,"accession_number":"0000950170-25-019314","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA reports Q4 2024 net loss of $130.3M; cash ~$1.1B, funds operations into at least 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities of ~$1.1B as of Dec 31, 2024, up from $632.6M in 2023.","Net loss for Q4 2024 was $130.3M vs $34.0M in Q4 2023; full-year net loss $274.5M vs $113.0M.","R&D expenses surged to $140.2M in Q4 2024 from $38.8M, driven by $75M upfront for IDE849 license from Hengrui.","Over 230 patients enrolled in darovasertib + crizotinib Phase 2/3 in 1L HLA-A2-negative MUM; median PFS readout by year-end 2025.","Announced three development candidates: IDE892 (PRMT5), IDE034 (B7H3/PTK7 ADC), IDE251 (KAT6/7); INDs targeted in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":7000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176152,"accession_number":"0001193125-25-023076","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEAYA appoints Joshua Bleharski as CFO, effective May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Bleharski, Ph.D., age 50, appointed Chief Financial Officer, effective early May 2025.","Bleharski joins from J.P. Morgan, where he spent 17 years, most recently as Managing Director and Global Co-Head of Biopharma.","Holds B.S. in Biology from Duke, Ph.D. in Immunology from UCLA, and MBA from UC Berkeley Haas.","Compensation terms for Bleharski will be disclosed later via an amendment to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193058,"accession_number":"0001193125-24-286169","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IDEAYA licenses DLL3 ADC SHR-4849 from Hengrui; total potential payments $1.045B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive worldwide license (ex-Greater China) for Phase 1 DLL3-targeting Topo-I-payload ADC SHR-4849.","Hengrui Pharma eligible for $75M upfront, up to $200M development/regulatory milestones, plus commercial milestones and mid-single to low-double digit royalties.","In 11 evaluable SCLC patients at therapeutic doses, 8 partial responses observed (~73% ORR, including unconfirmed) with manageable safety profile.","IDEAYA targets US IND filing for SHR-4849 in H1 2025; cash runway guided to at least 2028 unchanged.","SHR-4849 offers rational combination opportunity with IDEAYA's Phase 1 PARG inhibitor IDE161 for enhanced preclinical efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193057,"accession_number":"0000950170-24-120257","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA reports Q3 net loss of $51.8M; cash $1.2B; progress in darovasertib and IDE397 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $51.8M for Q3 2024; R&D expenses $57.2M; G&A $9.7M.","Cash, equivalents and marketable securities of $1.2B as of Sep 30, 2024, up from $952.7M due to $283.8M follow-on net proceeds.","Darovasertib + crizotinib 1L UM registration trial enrollment exceeded 150 patients; successful FDA Type C meeting for neoadjuvant Ph3 targeting H1 2025 initiation.","IDE397 Phase 1 expansion at ENA 2024 showed 40% confirmed ORR in MTAP-deletion UC, 38% in squamous NSCLC, and 22% in adeno NSCLC.","IND clearance for IDE275 (Werner helicase) earned $7M milestone from GSK; targeting 3 DC nominations in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193056,"accession_number":"0001193125-24-243413","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA reports 33% ORR in Phase 1 IDE397 in MTAP-deletion urothelial cancer and NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate 33% (1 CR, 8 PR) in 27 evaluable patients; all 9 responses confirmed.","Confirmed ORR by tumor: 40% (4/10) urothelial, 38% (3/8) squamous NSCLC, 22% (2/9) adenocarcinoma NSCLC.","Disease control rate 93%; median treatment duration >6.2 months; 15 of 27 patients still on treatment.","ctDNA molecular response rate 81% (≥50% reduction) and 33% (≥90% reduction) in 21 reportable patients.","Favorable safety: 18% Grade 3+ drug-related AEs; no drug-related SAEs or discontinuations; IDE397 + Trodelvy combo to start Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193055,"accession_number":"0001193125-24-233038","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IDEAYA to present Phase 1 expansion data for IDE397 in MTAP-deletion NSCLC/urothelial at EORTC-NCI-AACR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.","Presenter is Dr. Benjamin Herzberg, Columbia University; abstract #501 LBA.","Additional poster: preclinical data for MAT2A + PRMT5 combination in MTAP-deleted tumors (poster PB204).","Additional poster: preclinical data for IDE161, a PARG inhibitor targeting solid tumors (poster PB337).","EORTC-NCI-AACR Symposium in Barcelona, Oct 23-25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209435,"accession_number":"0001193125-24-223230","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA reports positive Phase 2 darovasertib data in neoadjuvant uveal melanoma; FDA supports registrational Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["59% of 49 evaluable patients had >=20% ocular tumor shrinkage; 49% had >=30% shrinkage by product of diameters.","Eye preservation rate of 61% in enucleation patients; 11% Grade 3+ AEs, 5% serious AEs, 3% discontinuation rate.","FDA guidance: primary endpoint eye preservation for enucleation, time to vision loss for brachytherapy; ORR potential surrogate.","Phase 3 planned with ~400 patients, two cohorts; 300mg BID dose; broad label possible for low/intermediate/high risk.","Neoadjuvant UM annual incidence ~12,000 in NA/Europe/Australia; IDEAYA owns commercial rights (ex-Novartis license)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209434,"accession_number":"0000950170-24-091175","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA Q2 net loss $52.8M; darovasertib neoadjuvant UM shows tumor shrinkage; IDE397 39% ORR in MTAP-deletion tumors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.","Cash $952.7M at June 30; July public offering netted $283.8M, extending runway into at least 2028.","Darovasertib in neoadjuvant UM: Phase 2 enrolled >50 patients; median tumor shrinkage ~72% volume; FDA Type C meeting in Q3.","IDE397 in MTAP-deletion tumors: 39% ORR (1 CR, 6 PR), 94% DCR in 18 evaluable patients; selected 30 mg expansion dose.","Entered option/license agreement with Biocytogen for B7H3/PTK7 BsADC; DC nomination targeted H2 2024; potential milestones $406.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209433,"accession_number":"0000950170-24-088200","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"IDEAYA enters option/license deal with Biocytogen for B7H3/PTK7 BsADC; total potential $406.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total potential payments of $406.5M including $100M development/regulatory milestones and single-digit royalties.","Option for exclusive worldwide license; upfront and option exercise fees up to $6.5M.","Targets B7H3/PTK7 co-expression in lung, colorectal, head and neck cancers with double-digit prevalence.","Development candidate nomination targeted for H2 2024; potential combo with DDR pipeline including IDE161 (PARG)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209432,"accession_number":"0001193125-24-177726","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"IDEAYA Biosciences completes $283.8M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 8,355,714 common shares and pre-funded warrants for 285,715 shares at $35.00 per share/$34.9999 per warrant.","Net proceeds of approximately $283.8 million after underwriting discounts and expenses.","Underwriters' option for 1,127,142 additional shares exercised in full.","Underwriters include J.P. Morgan, Goldman Sachs, Jefferies, RBC Capital Markets.","Directors and officers subject to 60-day lock-up on share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209431,"accession_number":"0001193125-24-176736","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"IDEAYA reports preliminary Q2 cash of $952.7M; sells 922k shares via ATM at ~$40.40","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents & marketable securities of ~$952.7M as of June 30, 2024 (unaudited).","Sold 922,000 shares via ATM at weighted avg price of ~$40.40/share between Apr 1 and Jul 5, 2024.","Remaining ATM capacity of ~$182.1M of common stock available for sale as of July 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209430,"accession_number":"0001193125-24-175867","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA reports 39% ORR in IDE397 Phase 2 monotherapy for MTAP-deletion cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Overall response rate 39% (1 CR, 6 PRs by RECIST 1.1) in 18 evaluable MTAP-deletion urothelial cancer and NSCLC patients.","Disease control rate 94%; tumor shrinkage observed in 14/18 evaluable patients; 5 of 7 responses still ongoing.","81% ctDNA molecular response rate (13/16 reportable patients with ≥50% ctDNA reduction).","Favorable safety: 5.6% Grade 3+ drug-related AE (1 asthenia); no drug-related discontinuations.","No FDA-approved therapies for MTAP-deletion solid tumors; IDE397 30 mg QD tablet enables long-term dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227448,"accession_number":"0001193125-24-169573","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"IDEAYA Biosciences CLO Jason Throne resigns effective July 11, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Throne voluntarily resigned as Chief Legal Officer and Secretary.","Resignation effective July 11, 2024, due to personal reasons.","No disagreement with company operations, policies, or practices.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227447,"accession_number":"0000950170-24-067644","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.","Median tumor shrinkage 47% (max volume change) in 12 enucleation patients; 67% had >30% shrinkage after 6 months.","Company-sponsored Phase 2: 8 patients at ≥4 months showed median tumor volume shrinkage 72%; majority of enucleation patients converted to eye saved.","Drug-related AEs predominantly Grade 1-2; no drug-related serious AEs in either trial.","Data presented at ASCO 2024; trial enrolled over 40 patients across 14+ sites globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227446,"accession_number":"0000950170-24-067407","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"IDEAYA Biosciences annual meeting results: all four proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dr. Terry J. Rosen (54.5M for) and Wendy L. Yarno (64.2M for) as Class II directors; 1.8M and 2.2M broker non-votes.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024: 70.9M for, 6,295 against.","Advisory say-on-pay approved with 62.9M for, 4.6M against, 1.6M abstentions, 1.7M broker non-votes.","Advisory vote on frequency set at 1 year: 66.2M for 1 year, 1.3M for 3 years, 1.7M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227445,"accession_number":"0000950170-24-053900","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDEAYA Q1 net loss $39.6M, cash $941M; darovasertib UM data at ASCO, Werner IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.6M for Q1 2024; cash, equivalents and marketable securities $941.4M, projected to fund operations into 2028.","Darovasertib neoadjuvant UM Phase 2 IST oral presentation at ASCO 2024; company-sponsored update on >30 patients and FDA guidance targeted H2 2024.","Selected Phase 2 dose for IDE397 in MTAP-deletion squamous NSCLC based on multiple PRs by RECIST 1.1; multiple PRs also in MTAP bladder cancer.","IND-enabling GLP tox completed for Werner Helicase inhibitor with GSK; IND filing targeted H2 2024 as 5th first-in-class clinical program.","Targeting FPI for IDE397+Trodelvy in MTAP bladder cancer mid-2024; Phase 2 expansion for IDE161 in HRD and combo with KEYTRUDA in endometrial cancer in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246319,"accession_number":"0000950170-24-029619","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"IDEAYA Enters Clinical Collaboration with Merck to Evaluate IDE161 + KEYTRUDA in Endometrial Cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial will test IDE161 (PARG inhibitor) + KEYTRUDA in MSI-high and MSS endometrial cancer.","Merck provides KEYTRUDA at no cost; IDEAYA sponsors the trial and pays study costs.","Each party retains full commercial rights to its own compound as monotherapy or combination.","IDE161 has FDA Fast-Track designation for BRCA1/2 ovarian and breast cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246318,"accession_number":"0000950170-24-016758","cik":1676725,"company_name":"IDEAYA Biosciences, Inc.","ticker":"IDYA","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IDYA reports Q4 net loss $34M, cash $632.6M; multiple 2024 milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $632.6M at Dec 31, 2023; Jan 2024 ATM raised ~$352M gross ($342.3M net); runway into 2028.","Q4 net loss $34.0M (vs $24.2M); FY 2023 net loss $113.0M (vs $58.7M). R&D spend $38.8M Q4.","Targeting two Phase 2 efficacy updates for darovasertib in neoadjuvant uveal melanoma mid-2024, plus FDA guidance.","Gilead collaboration to evaluate IDE397 + Trodelvy in MTAP-deletion bladder cancer; FPI mid-2024.","Werner helicase IND filing targeted 2024; $7M milestone on clearance. GSK collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":23385000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2551481285.803279,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}